Importantly, recent research has highlighted the efficacy of glucagon-like peptide-1 (GLP-1) agonists in reducing the psoriasis area and severity index and fasting plasma glucose in patients with psoriasis and diabetes mellitus [29]. Here, GCG is linked to diabetes mellitus.